Bioventus (BVS) Accounts Payables (2020 - 2026)

Bioventus' Accounts Payables history runs 7 years deep, the most recent figure standing at $24.0 million for Q1 2026.

• Quarterly Accounts Payables rose 25.28% year-over-year to $24.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.0 million (up 25.28% YoY) and the FY2025 annual result came in at $10.9 million, down 53.87% from the prior year.
• Accounts Payables was $24.0 million for Q1 2026 at Bioventus, up from $10.9 million in the prior quarter.
• Across five years, Accounts Payables topped out at $41.4 million in Q3 2023 and bottomed at $10.9 million in Q4 2025.
• A 5-year average of $24.0 million and a median of $23.7 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables surged 160.45% — and 2025, when it tumbled 53.87%.
• Bioventus' Accounts Payables stood at $36.7 million in 2022, then plunged by 37.22% to $23.0 million in 2023, then grew by 2.83% to $23.7 million in 2024, then tumbled by 53.87% to $10.9 million in 2025, then jumped by 120.08% to $24.0 million in 2026.
• Business Quant data shows BVS's Accounts Payables at $24.0 million in Q1 2026, $10.9 million in Q4 2025, and $26.6 million in Q3 2025.